PMP22 and Charcot-Marie-Tooth disease type 1A: In contrast to progesterone antagonists [32,34], the growth factor neuregulin [27] or, more recently, Pmp22-targeting antisense oligonucleotides [35,36], a preclinical early treatment trial in young CMT1A rats with PXT3003 is more easily translatable to young adults or even children with CMT1A due to its good safety profile.